NASDAQ:PHVS Pharvaris Q4 2025 Earnings Report $32.97 +1.51 (+4.80%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pharvaris EPS ResultsActual EPS-$0.84Consensus EPS -$0.69Beat/MissMissed by -$0.15One Year Ago EPSN/APharvaris Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APharvaris Announcement DetailsQuarterQ4 2025Date4/3/2026TimeBefore Market OpensConference Call DateThursday, April 9, 2026Conference Call Time12:30PM ETUpcoming EarningsPharvaris' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (20-F)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F)Annual report Pharvaris Earnings HeadlinesData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026June 15 at 8:44 AM | finance.yahoo.comPharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026 - SlideshowJune 12, 2026 | seekingalpha.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 17 at 1:00 AM | InvestorPlace (Ad)Pharvaris Announces Annual General Meeting of ShareholdersJune 11, 2026 | globenewswire.comPharvaris (NASDAQ:PHVS) Raised to Hold at Wall Street ZenJune 6, 2026 | americanbankingnews.comPharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy Conference - SlideshowMay 30, 2026 | seekingalpha.comSee More Pharvaris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email. Email Address About PharvarisPharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes. The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies. Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization. Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.View Pharvaris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Okta’s AI Moment May Be Bigger Than Investors RealizeDave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround PlanMicrosoft’s Xbox Problem Is Bigger Than a Console WarFlying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBread’s Comeback Is Real—But Is the Easy Money Gone?Strategy’s Bitcoin Rally Has a Hidden EngineOllie's Stock Has Lagged Despite Earnings Beats—What's Holding It Back? Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
